Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Italian Stock Exchange  >  Recordati    REC   IT0003828271

RECORDATI

(REC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Italian Stock Exchange
11/23/2020 11/24/2020 11/25/2020 11/26/2020 11/27/2020 Date
44.99(c) 43.83(c) 44.42(c) 44.86(c) 45.19 Last
386 253 508 084 391 305 165 987 184 317 Volume
-2.75% -2.58% +1.35% +0.99% +0.74% Change
More quotes
Financials
Sales 2020 1 475 M 1 759 M 1 759 M
Net income 2020 379 M 452 M 452 M
Net Debt 2020 814 M 971 M 971 M
P/E ratio 2020 25,4x
Yield 2020 2,25%
Sales 2021 1 596 M 1 904 M 1 904 M
Net income 2021 401 M 479 M 479 M
Net Debt 2021 845 M 1 007 M 1 007 M
P/E ratio 2021 23,5x
Yield 2021 2,40%
Capitalization 9 233 M 10 993 M 11 009 M
EV / Sales 2020 6,81x
EV / Sales 2021 6,31x
Nbr of Employees 4 323
Free-Float 46,6%
More Financials
Company
Recordati specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical and OTC products (83.1%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.; - medicines for rare diseases (16.9%). Net sales break down geographically as follows: Italy (19.1%), Europe (68. 
More about the company
Notations Surperformance© of Recordati
Trading Rating : Investor Rating :
More Ratings
All news about RECORDATI
11/23RECORDATI : Ex-dividend day for interim dividend
FA
11/13RECORDATI : Call to an extraordinary general meeting of the shareholders 17.12.2..
PU
11/06RECORDATI : Latest Company presentation
PU
11/06RECORDATI : Ultima presentazione del gruppo
PU
10/29RECORDATI : 2020 First nine months results
PU
10/29RECORDATI : Profit growth in the first nine months of 2020. revenues -0.6%, ebit..
PU
10/29RECORDATI : Profit growth in the first nine months of 2020. revenues -0.6%, ebit..
AQ
10/29RECORDATI : Profit growth in the first nine months of 2020. revenues -0.6%, ebit..
AQ
10/29RECORDATI : Profit growth in the first nine months of 2020. revenues -0.6%, ebit..
GL
10/29RECORDATI : Press Release
CO
10/29RECORDATI : 3rd quarter results
CO
10/07RECORDATI : Publication of the information document relating to major transactio..
PU
10/06RECORDATI : FILING OF THE MERGER PLAN RELATING TO THE MERGER BY ABSORPTION OF RO..
PU
10/05RECORDATI : Reverse merger of Rossini Investimenti S.p.A. and Fimei S.p.A. with ..
PU
10/01REVERSE MERGER OF ROSSINI INVESTIMEN : 2 ottobre 2020 - ore 8.30Dial in numbers:..
PU
More news
News in other languages on RECORDATI
11/02L'Amérique, l'Amérique, je veux l'avoir et je l'aurai
11/02AVIS D'ANALYSTES DU JOUR : Amplifon, Barco, Fiat Chrysler, Getlink, Nestlé, Nexa..
10/30RECORDATI : un troisième trimestre en deçà des attentes:
10/19Berenberg belässt Dermapharm auf 'Buy' - Ziel 48 Euro
08/04Toujours les mêmes qui gagnent ?
More news
Chart RECORDATI
Duration : Period :
Recordati Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RECORDATI
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 46,64 €
Last Close Price 44,86 €
Spread / Highest target 18,1%
Spread / Average Target 3,96%
Spread / Lowest Target -10,8%
EPS Revisions
Managers
NameTitle
Andrea Recordati Chief Executive Officer
Alfredo Altavilla Chairman
Luigi Felice La Corte Group Chief Financial Officer
Raffaele Sabia SVP-Pharmaceutical Research & Development
Fritz Squindo Director & Group General Manager
Sector and Competitors
1st jan.Capitalization (M$)
RECORDATI19.40%10 993
JOHNSON & JOHNSON-1.50%378 244
ROCHE HOLDING AG-3.47%285 939
NOVARTIS AG-11.58%203 854
PFIZER INC.-1.59%203 048
MERCK & CO., INC.-11.97%202 555